Chimeric protein
The present invention provides a chimeric protein having the formula: Casp-Ht1-Ht2 wherein Casp is a caspase domain; Ht1 is a first heterodimerization domain; and Ht2 is a second heterodimerization domain and wherein, in the presence of a chemical inducer of dimerization (CID), an identical pair of the chimeric proteins interact such that Ht1 from one chimeric protein heterodimerizes with Ht2 from the other chimeric protein, causing homodimerization of the two caspase domains. The invention also provides a cell comprising such a protein and its use in adoptive cell therapy.
1. A chimeric protein having the formula:
Ht1-Ht2-Casp, wherein
Casp is a caspase domain;
Ht1 is a first heterodimerization domain; and
Ht2 is a second heterodimerization domain;
wherein one heterodimerization domain comprises an FK506-binding protein (FKBP) and the other heterodimerization domain comprises an FRB domain of mTOR;
and wherein, in the presence of rapamycin or a rapamycin analog, an identical pair of the chimeric proteins interact such that Ht1 from one chimeric protein heterodimerizes with Ht2 from the other chimeric protein, causing homodimerization of the two caspase domains.
2. The chimeric protein according to claim 1 , wherein Ht1 comprises FRB and Ht2 comprises FKBP.
3. A nucleic acid comprising a nucleotide sequence which encodes a chimeric protein having the formula: Ht1-Ht2-Casp,
wherein Casp is a caspase domain; Ht1 is a first heterodimerization domain; and Ht2 is a second heterodimerization domain;
wherein one heterodimerization domain comprises an FK506-binding protein (FKBP) and the other heterodimerization domain comprises an FRB domain of mTOR.
4. The nucleic acid construct which comprises one or more nucleic acid(s) according to claim 3 and a nucleic acid that comprises a nucleotide sequence encoding a T-cell receptor (TCR) or chimeric antigen receptor (CAR).
5. A vector which comprises a nucleic acid according to claim 3 .
6. A cell which expresses a chimeric protein according to claim 1 .
7. The cell according to claim 6 , which is a haematopoietic stem cell, a lymphocyte or a T cell.
8. A method for making a cell which expresses a chimeric protein, the method comprising the step of transducing or transfecting a cell with a vector according to claim 5 .
9. A method for deleting a cell according to claim 6 , which comprises the step of exposing the cells to a rapamycin or a rapamycin analog.
10. A method for preventing and/or treating a pathological immune reaction in a subject caused by administration of a cell according to claim 6 to the subject, which comprises the step of administering rapamycin or a rapamycin analog to the subject.
11. The method according to claim 10 , wherein the pathological immune reaction is selected from the following group: graft-versus-host disease; on-target, off-tumour toxicity; immune activation syndrome; and lymphoproliferative disorders.
12. A vector which comprises a nucleic acid construct according to claim 4 .
13. A method for making a cell which expresses a chimeric protein, the method comprising transducing or transfecting a cell with a vector according to claim 12 .